Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2\(^+\) Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

Amylou C. Dueck\(^1\), Monica M. Reinholz\(^3\), Xochiquetzal J. Geiger\(^6\), Kathleen Tenner\(^4\), Karla Ballman\(^4\), Robert B. Jenkins\(^3\), Darren Riehle\(^3\), Beiyun Chen\(^3\), Ann E. McCullough\(^2\), Nancy E. Davidson\(^8\), Silvana Martino\(^9\), George W. Sledge\(^10\), Peter A. Kaufman\(^11\), Leila A. Kutteh\(^12\), Julie Gralow\(^13\), Lyndsay N. Harris\(^14\), James N. Ingle\(^5\), Wilma L. Lingle\(^3\), and Edith A. Perez\(^7\)


doi: 10.1158/1078-0432.CCR-13-0558

Clinical Cancer Research

Predictive Biomarkers and Personalized Medicine

Abstract

**Purpose:** This study investigated the association between tumor MYC protein expression and disease-free survival (DFS) of patients randomized to receive chemotherapy alone (Arm A) or chemotherapy with sequential (Arm B) or concurrent trastuzumab (Arm C) in the N9831 (Alliance) adjuvant HER2\(^+\) trastuzumab breast cancer trial.

**Experimental Design:** This analysis included 1,736 patients randomized to Arms A, B, and C on N9831. Nuclear MYC protein expression was determined in tissue microarray sections containing three biopsies per patient or whole tissue sections using standard immunohistochemistry (clone 9E10). A tumor was considered positive for MYC protein overexpression (MYC\(^+\)) if the nuclear 3+ staining percentage was more than 30%.

**Results:** Five hundred and seventy-four (33%) tumors were MYC\(^+\). MYC\(^+\) was associated with hormone receptor positivity (\(\chi^2, P = 0.006\)), tumors 2 cm or more (\(\chi^2, P = 0.02\)), and a higher rate of nodal positivity (\(\chi^2, P < 0.001\)). HRs for DFS (median follow-up: 6.1 years) for Arm C versus A were 0.52 (\(P = 0.006\)) and 0.65 (\(P = 0.006\)) for patients with MYC\(^+\) and MYC\(^-\) tumors, respectively (\(P_{\text{interaction}} = 0.40\)). For Arm B versus A, HRs for patients with MYC\(^+\) and MYC\(^-\) tumors were 0.79 (\(P = 0.21\)) and 0.74 (\(P = 0.04\)), respectively (\(P_{\text{interaction}} = 0.71\)). For Arm C versus B, HRs for patients with MYC\(^+\) and MYC\(^-\) tumors were 0.56 (\(P = 0.02\)) and 0.89 (\(P = 0.49\)), respectively (\(P_{\text{interaction}} = 0.17\)).

**Conclusions:** Our data do not support an impact of tumor MYC protein expression on differential benefit from adjuvant trastuzumab. *Clin Cancer Res; 19(20); 5798–807. ©2013 AACR.*

**Introduction**

Patients with human EGF receptor-2–positive (HER2\(^+\)) breast tumors have greatly benefited from the development of trastuzumab, a humanized monoclonal antibody directed against HER2 (1). Trastuzumab has proven to prolong the survival of women with metastatic breast cancer and significantly increase disease-free survival (DFS) of patients with HER2\(^+\) early breast cancer (2, 3). However, many women who receive trastuzumab for advanced disease develop tumor progression within 1 year, and 15% to 25% of women diagnosed with HER2\(^+\) early disease develop tumor relapse within 3 years, despite therapy (4). Thus, identifying molecular markers that could predict the patients who are most likely to benefit from trastuzumab is an important research and clinical goal.

MYC is one of several markers reported to be involved in trastuzumab sensitivity and resistance. The MYC oncoprotein is a pleiotropic transcription factor and key regulator of cell growth, proliferation, metabolism, differentiation, apoptosis, and pathways that regulate genome stability and cell...
Translational Relevance

Despite therapy, up to a quarter of women diagnosed with HER2+ early-stage breast cancer develop tumor relapse within 3 years. Identifying markers that could help predict trastuzumab benefit is therefore an important clinical goal. Previous evidence from B31 and N9831 suggested that MYC gene copy number anomalies may be associated with additional benefit to adjuvant trastuzumab. We then investigated the association between MYC protein overexpression (MYC+; nuclear 3+ staining in >30% tumor cells) and disease-free survival of patients in N9831. Patients with MYC+ and MYC- tumors both significantly benefited from concurrent trastuzumab compared with standard chemotherapy alone, and the level of benefit was not significantly different. Patients with MYC+ but not with MYC- tumors significantly benefited from concurrent trastuzumab compared with sequential trastuzumab. Our N9831 data indicate that MYC protein expression is not significantly associated with differential benefit to concurrent adjuvant trastuzumab with chemotherapy.

MYC Protein Expression on Benefit of Adjuvant Trastuzumab

analysis of the role of MYC protein overexpression in trastuzumab sensitivity. We therefore evaluated the association between MYC protein expression and DFS of patients randomized to receive chemotherapy alone (Arm A) or chemotherapy with sequential (Arm B) or concurrent trastuzumab (Arm C) on N9831.

Materials and Methods

Patients

The N9831 trial (NCI00005970) was a phase III trial in which patients were randomized to three arms: Arm A, doxorubicin and cyclophosphamide followed by weekly paclitaxel; Arm B, same as Arm A but followed by 1 year of sequential trastuzumab; and Arm C, same as Arm A but with 1-year concurrent trastuzumab, started the same day as weekly paclitaxel (Supplementary Fig. S1). Patients randomly assigned to the concurrent trastuzumab arm had a significantly increased DFS \( P < 0.001; \) stratified HR, 0.52; 95% confidence interval (CI), 0.45–0.60 and overall survival (OS; \( P < 0.001; \) stratified HR, 0.61; 95% CI, 0.50–0.75) compared with patients assigned to the control arm (2). In the N9831 comparison of sequential versus concurrent trastuzumab chemotherapy, there was an increase in DFS with concurrent trastuzumab \( P = 0.02; \) HR, 0.77; 99.9% CI, 0.53–1.11; ref. 11). The 5-year OS rate for the sequential and concurrent arms was estimated at 89.7% (95% CI, 87.7%–91.8%) and 91.9% (95% CI, 90.0%–93.7%), respectively.

All patients’ tumors included in these analyses were tested for HER2 protein overexpression or gene amplification at a central laboratory (Mayo Clinic). Patients were considered positive for HER2 according to the U.S. Food and Drug Administration-approved guidelines (immunohistochemistry, IHC: complete 3+ membrane staining \( \geq 10\% \) invasive cells; FISH: \( \text{HER2}/\text{CEP}17 \) ratio \( \geq 2.0; \) refs. 12, 13). N9831 was approved by all treating sites’ Institutional Review Boards, and all patients signed informed consent. The Mayo Institutional Review Board and the Correlative Science Committee of the North American Breast Cancer Group approved this translational study.

This study included 1,736 eligible/consented patients with sufficient tissue for analyses. Six hundred and eighty-two were excluded (failed central review: 283, ineligible: 61, canceled: 28, no consent: 187, lost to follow-up: 123) and 1,087 had insufficient tissue for analyses (Supplementary Fig. S2). The number of patients represented on tissue microarrays (TMA) with evaluable tissue cores were 1,216 and the number of different patients with evaluable whole sections were 520 (Supplementary Fig. S2).

Tissue microarrays and whole tissue sections

TMAs were constructed as part of the translational study component of N9831 using an ATA-27 automated TMA construction system (Beecher Instruments) as described previously (10). Each TMA contained control biopsies from non-neoplastic human liver, placenta, and tonsil tissues. Whole tissue sections from tumors not represented on TMAs were also examined. We evaluated the concordance
between TMA and whole section protein analyses of 86 independent breast tumors and observed a concordance of 90% and 92% using the minimum and maximum TMA scores, respectively, of nuclear 3+ staining in more than 30% invasive cells.

### MYC testing methods

Standard laboratory protocols were followed for IHC and quality control measures. Antigen retrieval was conducted on deparaffinized whole or TMA sections (5 μm) using preheated citrate buffer (98°C; 40 minutes). The tissue sections were treated with Peroxidase Blocking Reagent (Dako) and serum-free Protein Block (Dako) before IHC staining for c-MYC (mouse monoclonal clone 9E10; Sigma-Aldrich, #5546; dilution 1:250; 60-minute incubation) using a Dako Autostainer Plus (Reference #S3800). The sections were incubated in secondary antibody (Dako Envision Plus Dual Link Horseradish Peroxidase Kit; Dako # K4061). The high-sensitivity 3,3′-diaminobenzidine (DAB+) chromogenic substrate system (Betazoid DAB, Biocare) was used for colorimetric visualization followed by counter staining with hematoxylin.

### Table 1. Patient characteristics by % 3+ nuclear staining

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>≤30% 3+ Nuclear staining N = 1,162 (67%)</th>
<th>&gt;30% 3+ Nuclear staining N = 574 (33%)</th>
<th>χ² P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (median)</td>
<td>50 (22–80)</td>
<td>49 (25–79)</td>
<td></td>
</tr>
<tr>
<td>Age group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;40</td>
<td>200 (17)</td>
<td>106 (18)</td>
<td>0.49a</td>
</tr>
<tr>
<td>40–49</td>
<td>370 (32)</td>
<td>185 (32)</td>
<td></td>
</tr>
<tr>
<td>50–59</td>
<td>379 (33)</td>
<td>181 (32)</td>
<td></td>
</tr>
<tr>
<td>≥60</td>
<td>213 (18)</td>
<td>102 (18)</td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>993 (85)</td>
<td>495 (86)</td>
<td>0.66</td>
</tr>
<tr>
<td>Other</td>
<td>169 (15)</td>
<td>79 (14)</td>
<td></td>
</tr>
<tr>
<td>Menopausal status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre</td>
<td>610 (52)</td>
<td>316 (55)</td>
<td>0.32</td>
</tr>
<tr>
<td>Post</td>
<td>552 (48)</td>
<td>258 (45)</td>
<td></td>
</tr>
<tr>
<td>ER/PR Status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER or PR Positive</td>
<td>584 (50)</td>
<td>329 (57)</td>
<td>0.006</td>
</tr>
<tr>
<td>Other</td>
<td>578 (50)</td>
<td>245 (43)</td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast conserving</td>
<td>482 (41)</td>
<td>202 (35)</td>
<td>0.01</td>
</tr>
<tr>
<td>Mastectomy</td>
<td>680 (58)</td>
<td>372 (65)</td>
<td></td>
</tr>
<tr>
<td>Nodal statusab</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Node positive (1–3+ nodes)</td>
<td>429 (37)</td>
<td>249 (43)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Node positive (4–9+ nodes)</td>
<td>298 (26)</td>
<td>150 (26)</td>
<td></td>
</tr>
<tr>
<td>Node positive (≥10+ nodes)</td>
<td>135 (12)</td>
<td>90 (16)</td>
<td></td>
</tr>
<tr>
<td>Node negative (no pos. nodes)</td>
<td>90 (8)</td>
<td>23 (4)</td>
<td></td>
</tr>
<tr>
<td>Positive sentinel node</td>
<td>94 (8)</td>
<td>38 (7)</td>
<td></td>
</tr>
<tr>
<td>Negative sentinel node</td>
<td>116 (10)</td>
<td>24 (4)</td>
<td></td>
</tr>
<tr>
<td>Predominant tumor histology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ductal</td>
<td>1,097 (94)</td>
<td>544 (95)</td>
<td>0.55</td>
</tr>
<tr>
<td>Lobular</td>
<td>33 (3)</td>
<td>19 (3)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>31 (3)</td>
<td>11 (2)</td>
<td></td>
</tr>
<tr>
<td>Missing</td>
<td>1</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Histologic tumor grade (Elston/Scarff-Bloom-Richardson)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well/intermediate</td>
<td>327 (28)</td>
<td>159 (28)</td>
<td>0.85</td>
</tr>
<tr>
<td>Poor</td>
<td>835 (72)</td>
<td>415 (72)</td>
<td></td>
</tr>
<tr>
<td>Pathologic tumor size</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 2 cm</td>
<td>384 (33)</td>
<td>159 (28)</td>
<td>0.02</td>
</tr>
<tr>
<td>≥ 2 cm</td>
<td>778 (67)</td>
<td>415 (72)</td>
<td></td>
</tr>
</tbody>
</table>

aMantel-Haenszel trend test.
bSentinel node findings are based on sentinel node dissection not followed by axillary dissection.

Abbreviations: ER, estrogen receptor; PR, progesterone receptor.
MYC protein overexpression (MYC\(^+\)) was defined as more than 30% of invasive cells with 3\(^+\) nuclear staining, based on the criteria used for HER2 protein overexpression established by the 2007 American Society of Clinical Oncologists/College of American Pathologists guidelines, as well as the lack of any widely accepted other criteria for MYC positivity in the literature (14). We also evaluated cytoplasmic MYC protein expression because MYC has been observed in the cytoplasm of tumor cells (5), which has been shown to be correlated with increased survival of patients with breast cancer (15).

**Statistical analysis**

The primary endpoint of N9831 was DFS and was defined as local, regional, or distant recurrence, contralateral breast cancer, another primary cancer (except squamous or basal cell carcinoma of the skin, carcinoma in situ of the cervix, or lobular carcinoma in situ of the breast), or death from any cause. Duration of DFS was defined as the time from registration to the first DFS event. DFS was estimated by the Kaplan–Meier method. Comparisons between Arms A, B, and C within subgroups were conducted using Cox proportional hazards models stratified by nodal status (1–3 vs. 4–9 vs. \(>10\) positive nodes vs. positive sentinel node only vs. negative sentinel node with no axillary nodal dissection vs. axillary nodal dissection with no positive nodes) and hormone receptor status (estrogen receptor positive and/or progesterone receptor positive vs. negative for both receptors). We tested MYC protein expression as a predictor for differential trastuzumab benefit between MYC subgroups using Cox proportional hazards models (also stratified by nodal status and hormone receptor status), which included a treatment arm by MYC subgroup interaction term. The maximum nuclear MYC protein expression of the whole section or of the replicate TMA biopsies was used for all analyses associated with patient outcome.

**Results**

**Study patients**

The trial N9831 registered 3,505 patients into Arms A (1,232 patients), B (1,216 patients), and C (1,057 patients) of which 1,736 patients (A: 584, B: 624, and C: 528) were included in the statistical analysis of MYC protein expression (Supplementary Fig. S2). The 1,769 patients who were excluded from analysis were excluded for the following reasons: failed central HER2 pathology review (283 patients), ineligible (61 patients), canceled before treatment initiation (28 patients), withdrew consent (187 patients), lost to follow-up (123 patients), and no/inadequate tissue or a technical failure of the assay (1,087 patients). The median follow-up time was 6.1 years (September 21, 2010).

The clinicopathological characteristics of the 1,736 patients enrolled on Arms A, B, and C reported herein were similar to the 1,087 consented and eligible patients on Arms A, B, and C excluded from analysis because of a lack of MYC results (Supplementary Table S1), except that included patients tended to have larger tumors. The clinicopathological characteristics of the 1,736 patients whose tumors

### Table 2. Correlation of MYC cytoplasmic staining with MYC nuclear staining

<table>
<thead>
<tr>
<th>MYC(% 3^+) nuclear staining (maximum across cores)</th>
<th>0%–9%</th>
<th>10%–30%</th>
<th>31%–60%</th>
<th>61%–100%</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>MYC(% 3^+) cytoplasmic staining (maximum across cores)</td>
<td>0%–9%</td>
<td>10%–30%</td>
<td>31%–60%</td>
<td>61%–100%</td>
<td>Total</td>
</tr>
<tr>
<td>0%–9%</td>
<td>536 (64%)</td>
<td>203 (24%)</td>
<td>78 (9%)</td>
<td>27 (3%)</td>
<td>844</td>
</tr>
<tr>
<td>10%–30%</td>
<td>118 (27%)</td>
<td>205 (46%)</td>
<td>75 (17%)</td>
<td>43 (10%)</td>
<td>441</td>
</tr>
<tr>
<td>31%–60%</td>
<td>11 (6%)</td>
<td>63 (32%)</td>
<td>74 (38%)</td>
<td>46 (24%)</td>
<td>194</td>
</tr>
<tr>
<td>61%–100%</td>
<td>3 (1%)</td>
<td>23 (9%)</td>
<td>54 (21%)</td>
<td>177 (69%)</td>
<td>257</td>
</tr>
<tr>
<td>Total</td>
<td>668</td>
<td>494</td>
<td>281</td>
<td>293</td>
<td>1,736</td>
</tr>
</tbody>
</table>

\(3^+\) cytoplasmic staining versus 3\(^+\) nuclear staining Mantel–Haenszel \(\chi^2 P \leq 0.001\).

\(\text{Spearman correlation between } 3^+\text{ cytoplasmic staining and } 3^+\text{nuclear staining } = 0.66 (P \leq 0.001).\)

### Table 3. Correlation of MYC nuclear staining with HER2 status

<table>
<thead>
<tr>
<th>HER2 IHC</th>
<th>0, 1+</th>
<th>2+</th>
<th>3+</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0%–9%</td>
<td>10 (23%)</td>
<td>70 (42%)</td>
<td>582 (38%)</td>
<td>662</td>
</tr>
<tr>
<td>10%–30%</td>
<td>10 (23%)</td>
<td>52 (31%)</td>
<td>432 (28%)</td>
<td>494</td>
</tr>
<tr>
<td>31%–60%</td>
<td>9 (20%)</td>
<td>16 (10%)</td>
<td>256 (17%)</td>
<td>281</td>
</tr>
<tr>
<td>61%–100%</td>
<td>15 (34%)</td>
<td>29 (17%)</td>
<td>249 (16%)</td>
<td>293</td>
</tr>
<tr>
<td>Total</td>
<td>44</td>
<td>167</td>
<td>1,519</td>
<td>1,730</td>
</tr>
</tbody>
</table>

\(\text{HER2 IHC staining versus } 3^+\text{nuclear staining Mantel–Haenszel } \chi^2 P = 0.10.\)
had nuclear 3+ MYC protein staining in >30% and ≤30% invasive tumor cells are shown in Table 1. Patients whose tumors had nuclear 3+ staining in more than 30% invasive cells had a higher rate of hormone receptor positivity, larger tumors, higher rate of mastectomy, and higher number of positive nodes than those patients whose tumors had nuclear 3+ MYC staining in 30% or less invasive tumor cells.

Distribution of MYC protein expression and relationship to HER2 protein expression

Of 1,736 patients with evaluable IHC analyses, 33% (n = 574) had more than 30% invasive cells, 28% (n = 494) had 10% to 30%, and 38% (n = 668) had less than 10% invasive cells with 3+ nuclear staining (Table 2). Nuclear and cytoplasmic 3+ staining had high agreement (81%; P < 0.001), and the correlation between 3+ nuclear and 3+ cytoplasmic staining was 0.66 (P < 0.001; Table 2). No significant association was observed between 3+ nuclear staining and HER2 IHC staining (P = 0.10; Table 3). Representative staining patterns of MYC protein expression are shown in Fig. 1.

Associations between MYC protein expression and DFS

No significant differences in DFS were observed between MYC+ and MYC− patients in any of the three

Figure 1. Representative IHC staining of MYC. A, representative staining of a specimen with more than 30% 3+ nuclear staining. B, representative staining of a specimen with less than 30% 3+ nuclear staining. C, representative staining of a specimen with 0% 3+ nuclear staining. ×10 magnification.
Table 4. DFS by MYC protein status within treatment arm

<table>
<thead>
<tr>
<th>Arm</th>
<th>3+ nuclear staining group</th>
<th>N  # Events</th>
<th>HR (95% CI)</th>
<th>P</th>
<th>DFS 3 y</th>
<th>DFS 5 y</th>
</tr>
</thead>
<tbody>
<tr>
<td>A (N = 584)</td>
<td>≤ 30%</td>
<td>390 108</td>
<td>1.04 (0.76–1.44)</td>
<td>0.77</td>
<td>81.8</td>
<td>74.9</td>
</tr>
<tr>
<td></td>
<td>&gt; 30%</td>
<td>194 58</td>
<td>1</td>
<td>79.3</td>
<td>71.4</td>
<td></td>
</tr>
<tr>
<td>B (N = 624)</td>
<td>≤ 30%</td>
<td>411 86</td>
<td>1.24 (0.87–1.76)</td>
<td>0.24</td>
<td>84.0</td>
<td>76.4</td>
</tr>
<tr>
<td></td>
<td>&gt; 30%</td>
<td>213 56</td>
<td>0.80 (0.51–1.27)</td>
<td>0.34</td>
<td>88.6</td>
<td>84.0</td>
</tr>
<tr>
<td>C (N = 528)</td>
<td>≤ 30%</td>
<td>361 66</td>
<td>1</td>
<td>91.0</td>
<td>88.0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt; 30%</td>
<td>167 28</td>
<td>0.77 79.3 71.4</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

arms (Table 4). Comparing DFS between arms C and A, patients with MYC− (Fig. 2A) and MYC+ (Fig. 2B) tumors had HRs of 0.52 (P = 0.006) and 0.65 (P = 0.006), respectively (Pinteraction = 0.40). Comparing DFS between arms B and A, patients with MYC− and MYC+ tumors had HRs of 0.79 (P = 0.21) and 0.74 (P = 0.04), respectively (Pinteraction = 0.71; Fig. 2A and B). Comparing DFS between arms C and B, patients with MYC− and MYC+ tumors had HRs 0.56 (P = 0.02) and 0.89 (P = 0.49), respectively (Pinteraction = 0.17; Fig. 2A and B).

In addition, patients with nuclear MYC staining of 3+ in 0% to 9%, 10% to 30%, 31% to 60%, and 61% to 100% of cells had HRs (C vs. A) of 0.68 (95% CI, 0.45–1.02), 0.64 (95% CI, 0.39–1.04), 0.63 (95% CI, 0.31–1.24), and 0.44 (95% CI, 0.23–0.84), respectively (Mantel–Haenszel χ2 = 0.30; Fig. 2C).

Discussion
MYC is a highly regulated and multifunctional transcription factor that regulates up to 15% of human genes and plays a central role in proliferation and malignant transformation of human and animal cells (16, 17). Previous evidence from B31 and N9831 suggested that MYC gene copy number anomalies may be associated with additional benefit to adjuvant trastuzumab (9, 10). Reports have been inconsistent with regard to the association of MYC protein expression and both clinicopathological characteristics and prognosis (5). To further explore these relationships, we designed the translational component of the N9831 trial to include an analysis of MYC protein overexpression in patients with HER2+ tumors.

Overall, we found that MYC protein expression was heterogeneous and characterized by both cytoplasmic and nuclear localization. We observed nuclear MYC protein overexpression (defined as nuclear 3+ staining in >30% invasive cells) in tumors from 33% of N9831 patients with HER2+ breast cancer. Early studies using IHC have shown that approximately 50% to 100% of breast cancer cases have MYC overexpression (5, 15, 18–22, 24, 29–32). In addition, strong MYC protein positivity was found in more than 20% nuclei, in 45% of 440 primary breast tumors (24), and 70% (36/51) showed 1+ or higher intensity staining (25) using the 9E10 clone used in our present study. Our study observed a lower incidence of 33% most likely due to our more strict cutoff criteria of 3+ staining in more than 30% nuclei and the fact that our patient population was HER2+ and not a general population of patients with breast cancer.

We also observed strong (3+) cytoplasmic staining in malignant cells, which correlated with strong (3+) nuclear staining. Other groups have found predominant cytoplasmic localization of MYC (15, 19), and this cytoplasmic staining has been associated with better survival (15). These results support the idea of nuclear exclusion of MYC, which has been observed in high-grade tumors, and could serve to attenuate select functions of MYC in later stages of disease progression (25, 26).

In this analysis, MYC nuclear protein overexpression was associated with hormone receptor positivity, nodal positivity, and larger tumors with associated increase in mastectomy rates. In agreement with our findings, MYC protein expression has been correlated with positive nodes (20, 27) and with estrogen receptor positivity (19). MYC also has been shown to be an estrogen-responsive gene (28). Although a significant association has not been consistently observed between MYC protein expression and breast tumor size (5, 19), MYC DNA levels (as detected by Southern blot analysis) have been correlated with tumor size (5), and the Ki-67 proliferation marker has been shown to correlate with MYC protein level (20). The association between MYC overexpression and tumor size in our study is consistent with MYC being a transcriptional activator of the cell proliferation pathway, an additional marker for the assessment of tumor cell proliferation (5). In contrast, other studies have shown no significant associations with estrogen receptors (18, 20–22, 24, 29) or with lymph node status (15, 18, 20–22, 24, 29–32).

We did not observe a significant difference in outcome between patients with and without MYC protein overexpression within any treatment arm and specifically, the DFS of N9831 patients treated with chemotherapy only was similar, regardless of MYC protein overexpression. Although this suggests that MYC overexpression is not a marker for prognosis, the true prognostic significance of MYC protein overexpression cannot be addressed in this study as all patients were treated with chemotherapy. This subgroup of patients also received protocol-specific radiotherapy and/or hormonal therapy. We did observe...
that MYC overexpression was associated with larger tumors and nodal positivity, both of which are powerful prognostic indicators. In N9831, however, radiotherapy was directed on the basis of surgery type and number of positive nodes. MYC overexpression was also associated with hormone receptor positivity, another disease characteristic, which was used in directing additional therapy, namely hormonal therapy. Therefore, one possibility to explain similar DFS within arm regardless of MYC overexpression status is that MYC may have disparate prognostic impact in subtypes of breast cancer, which washes out when treated differently and considered together. Another possibility is that MYC overexpression confers a worse prognosis but perhaps a greater response to chemotherapy, making it an overall null biomarker in this chemotherapy-treated population.

Several investigations have found that higher expression of MYC protein correlated with poorer outcome (33–35), whereas other studies have shown positive associations between MYC mRNA levels and survival (36) and between MYC protein levels and survival, most notably for node-negative patients (15). Our findings are consistent with previous findings that showed that MYC protein expression alone was not related to recurrence (30) and are supported by a limited number of studies that did not find associations between MYC expression and prognosis (19, 22). Importantly, however, we observed a benefit of...
shown to contribute to cancer cell survival under dual 
(42), and downregulation of MYC protein has been 
MYC protein is overexpressed in HER2 
settings would be lost. This may result in increased tumor 
downregulation on cancer cell survival in low glucose 
increasing MYC protein expression.

We also observed statistically significantly improved DFS 
from concurrent trastuzumab compared with sequential 
trastuzumab among patients with MYC protein overexpres-
sion, but not in patients without MYC protein overexpres-
sion. The interaction between MYC protein overexpression 
and timing of trastuzumab did not reach statistical signi-
ficance, but the large improvement in the HR for patients 
with MYC overexpression relative to patients without MYC 
overexpression gives rise to the speculation that the timing/
schedule of trastuzumab administration may be important 
in using MYC as an additional marker of trastuzumab 
sensitivity. As MYC induces cell proliferation and HER2 
breast tumors tend to have a high proliferation index (44–
46), those tumors with overexpression for both HER2 and 
MYC may be more susceptible to the growth inhibitory 
synergistic effects observed with the combination of che-
motherapy and trastuzumab (37, 38, 47).

Overall, our data indicate that MYC protein expression 
alone is not significantly associated with differential benefit 
to concurrent trastuzumab, but potentially could help dif-
ferentiate benefit between concurrent and sequential tras-
tuzumab treatment. Distinct mechanisms of regulation for 
MYC have been defined over the past decade, and several 
signal transduction pathways and regulatory mechanisms 
have evolved to keep MYC expression under tight control 
(17). Ongoing protein expression analyses of regulators and 
effectors of MYC (e.g., PTEN and insulin-like growth factor 
receptor-I; refs. 48, 49), and whole-genome expression 
profiling of N9831 tumors will provide important infor-
mation about the interactions between MYC and other 
pertinent proteins and genes and the effects of these inter-
actions on the sensitivity/resistance to adjuvant trastuzu-
mab. Understanding the full extent of the oncogenic effects 
of these interactions is critical to the development of more 
effective, targeted therapies for patients with breast cancer 
that exhibit HER2+ disease.

Disclosure of Potential Conflicts of Interest
P.A. Kaufman has a commercial research grant, has honoraria from 
speakers’ bureau, and is a consultant/advisory board member of Genentech. 
J. Gralow has a commercial research grant from Amgen, Novartis, Genentech, 
and Roche. No potential conflicts of interest were disclosed by the other 
authors.

Authors’ Contributions
Conception and design: A.C. Dueck, M.M. Reinholz, W. Lingle, E.A. Perez 
Development of methodology: A.C. Dueck, M.M. Reinholz, R.B. Jenkins, 
A.E. McCullough, W. Lingle, E.A. Perez 
Acquisition of data (provided animals, acquired and managed patients, 
provided facilities, etc.): M.M. Reinholz, M.M. Reinholz, R.B. Jenkins, D. 
Riehle, N.E. Davidson, S. Martino, G.W. Sledge, J. Gralow, L. Harris, J.N. 
Ingle, W. Lingle, E.A. Perez 
Analysis and interpretation of data (e.g., statistical analysis, biosta-
tistics, computational analysis): A.C. Dueck, M.M. Reinholz, K.S. Tenner, 
Writing, review, and/or revision of the manuscript: A.C. Dueck, M.M. 
Kuthe, J. Gralow, L. Harris, J.N. Ingle, W. Lingle, E.A. Perez 
Administrative, technical, or material support (i.e., reporting or orga-
nizing data, constructing databases): A.C. Dueck, M.M. Reinholz, K.S. 
Tenner, R.B. Jenkins 
Study supervision: M.M. Reinholz, R.B. Jenkins, P.A. Kaufman, E.A. Perez 
Grant Support
This work was supported by NIH grants CA25224-31 and CA114740 (PI: 
J.C. Buckner) for the North Central Cancer Treatment Group and associated 
Biopspecimen Resource, respectively, NIH grant CA129949 (PI: E.A. Perez/ 
M. M. Reinholz), and the Breast Cancer Research Foundation (PI: E.A. Perez). 
The costs of publication of this article were defrayed in part by the 
payment of page charges. This article must therefore be hereby marked 
advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate 
this fact.

Received February 26, 2013; revised July 9, 2013; accepted August 12, 
2013; published OnlineFirst August 21, 2013.

References
2. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, et al. Four-year follow-up of trastuzumab plus adjuvant che-
motherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCTCG N9831 and 
4. Bedard PL, de Azambuja E, Cardoso F. Beyond trastuzumab: over-
8. Neve RM, Sutherland H, Pullen N, Lane HA, Daly JM, Krek W, et al. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast 
Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMyc suggests pro-apoptotic function of dysregulated 


Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2 + Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

Amylou C. Dueck, Monica M. Reinholz, Xochiquetzal J. Geiger, et al.